Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism

Biochemical and Biophysical Research Communications

Volumn 410, Issue 4, 2011, Pages 803-808

  Ma, Xiao Ni ^a   Liu, Xiao Yun ^b,c   Yang, Yue Feng ^b   Xiao, Feng Jun ^a   Li, Qing Fang ^b   Yan, Jun ^a   Zhang, Qun Wei ^b   Wang, Li Sheng ^b   Li, Xue Yan ^a   Wang, Hua ^b  

^a LANZHOU UNIVERSITY OF TECHNOLOGY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hepatocellular carcinoma; Mcl 1; Migration; SCID mouse; Spred2

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN SPRED2; REGULATOR PROTEIN; SCATTER FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

ADENOVIRIDAE;

EID: 79960338021     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.068     Document Type: Article

References (27)

1. Bain I., McMaster P. Benign and malignant liver tumors. Surgery 1997, 15:169-174.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA. Cancer J. Clin. 2005, 55:74-108.
3. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. New. Engl. J. Med. 1999, 340:745-750.
4. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
5. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 36:1907-1917.
6. Bundschu K., Walter U., Schuh K. Getting a first clue about SPRED functions. Bioessays 2007, 29:897-907.
7. Kato R., Nonami A., Taketomi T., et al. Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation. Biochem. Biophys. Res. Commun. 2003, 302:767-772.
8. Sasaki A., Taketomi T., Wakioka T., Kato R., Yoshimura A. Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor-but not epidermal growth factor-induced ERK activation. J. Biol. Chem. 2001, 276:36804-36808.
9. Engelhardt C.M., Bundschu K., Messerschmitt M., et al. Expression and subcellular localization of Spred proteins in mouse and human tissues. Histochem. Cell Biol. 2004, 122:527-538.
10. Miyoshi K., Wakioka T., Nishinakamura H., et al. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization. Oncogene 2004, 23:5567-5576.
11. Nonami A., Kato R., Taniguchi K., et al. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J. Biol. Chem. 2004, 279:52543-52551.
12. King J.A.J., Straffon A.F.L., D'abaco G.M., et al. Distinct requirements for the Sprouty domain for functional activity of Spred proteins. Biochem. J. 2005, 388:445-454.
13. Inoue H., Kato R., Fukuyama S., et al. Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J. Exp. Med. 2005, 201:73-82.
14. Bonacchi A., Romagnani P., Romanelli R.G., et al. Signal transduction by the chemokine receptor CXCR3. J. Biol. Chem. 2001, 276:9945-9954.
15. Mardakheh K.F., Yekezare M., Machesky L.M., Heath J.K. Spred2 interaction with the late endosomal protein NBR1 down-regulates fibroblast growth factor receptor signaling. J. Cell Biol. 2009, 187:265-277.
16. Villar V., Kocic J., Santibanez J.F. Spred2 inhibits TGF-b1-induced urokinase type plasminogen activator expression, cell motility and epithelial mesenchymal transition. Int. J. Cancer 2010, 127:77-85.
17. Liu X.Y., Yang Y.F., Wu C.T., et al. Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells. Biochem. Biophys. Res. Commun. 2010, 393:637-642.
18. Yoshida T., Hisamoto T., Akiba J., et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006, 25:6056-6066.
19. Lee C.C., Putnam A.J., Miranti C.K., et al. Overexpression of Sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004, 23:5193-5202.
20. Yigzaw Y., Cartin L., Pierre S., Scholich K., Patel T.B. The C terminus of Sprouty is important for modulation of cellular migration and proliferation. J. Biol. Chem. 2001, 276:22742-22747.
21. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
22. Sridhar S.S., Hedley D., Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 2005, 4:677-685.
23. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
24. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14:342-346.
25. Steller H. Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449.
26. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 1997, 326:1-16.
27. Cryns V., Yuan J. Proteases to die for. Genes Dev. 1998, 12:1551-1570.